Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...